The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.
Data contradict Swiss drug major's claim that India does not respect IPR.
For a contiguous plot, the company may need to pay almost three times more for 40 acres at Hansalpur.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
Company has already put in place around 100 charging points across Delhi and Bangalore.
Many say trend could lead to concerns on manufacturing quality in Indian facilities.
Through messages via the BSNL network, the ministry plans to spread awareness among the public and ask people not to invest in suspicious companies.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Major hospital chains such as Max Healthcare, Apollo and Fortis are going online in a big way, to extend their operations into smaller towns and cities.
Not far back, in 2010, SRL Diagnostics, promoted by former Ranbaxy promoters Malvinder and Shivinder Singh, acquired the diagnostic services business of Piramal Healthcare for Rs 600 crore (Rs 6 billion).
Department of Pharmaceuticals asks NPPA to review Eli Lilly product prices.
On Monday, the Appellate Board upheld the compulsory licence granted to domestic firm Natco Pharma last year, against Bayer's patented anti-cancer drug Nexavar.
The panel of representatives from various ministries and chaired by B K Singh, director, department of pharmaceuticals, has suggested the government negotiate prices of patented medicines based on reference prices of such drugs in other countries such as Britain, Canada, France, Australia and New Zealand.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances